Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Samsung Medical Center
- Enrollment
- 81
- Locations
- 1
- Primary Endpoint
- Changes in appetite and eating behavior Rating Scales: Drug-related eating behavior questionnaire & Korean version of General Food Craving Questionnaire
Study Overview
Brief Summary
In this study, we are going to investigate quantitative and qualitative natures of appetite and eating-behavior changes induced by atypical antipsychotics, i.e., risperidone, olanzapine and aripiprazole, in schizophrenia patients.
Detailed Description
This is an observational study. 2 Self-report questionnaires assessing changes of appetite and eating behaviors after medication are applied to patients who have been receiving one of the three atypical antipsychotics. We are going to compare changes of appetite and eating behaviors after medication between three atypical antipsychotics and investigate the association between changes of appetite and eating behaviors and changes of weight after medication.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 19 Years to 59 Years (Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Patients meeting the DSM-IV criteria of schizophrenia, schizophreniform disorder, or schizoaffective disorder
- •Male and female patients aged 19~59
- •Patients receiving monotherapy with one of the three AAPs, i.e., olanzapine, risperidone, and aripiprazole for more than two and less than 24 months
- •Patients who had at least one-week antipsychotics-free periods before starting the above antipsychotics
- •Clinically stable and able to complete the questionnaires
- •Patients who sufficiently understand the objective of the study and sign informed consent form
Exclusion Criteria
- •Patients having any medical illness or taking any medicine affecting appetite and body weight
- •Patients with severe and unstable medical, neurological or systemic illnesses
- •Patients having any comorbid psychiatric disorders including substance use disorders and eating disorders.
- •Pregnant or breast-feeding women
Outcomes
Primary Outcomes
Changes in appetite and eating behavior Rating Scales: Drug-related eating behavior questionnaire & Korean version of General Food Craving Questionnaire
Time Frame: between 2 and 24months after starting medication
Secondary Outcomes
- Body mass index (BMI)(between 2 and 24 months after starting medication)